Repligen Corporation (RGEN) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript

Repligen reported 13% organic growth in Q2 2026, or 14% excluding the impact of a tariff refund, and raised full-year organic-growth guidance to 10.5%-13.5%, implying a 12% midpoint. First-half growth was 12%, supported by protein franchise growth of more than 50% and analytics growth of more than 30%, positioning the company for a stronger 2026 outlook.

Analysis

The investable signal is not simply higher growth, but mix: strength in process analytics and protein consumables implies customers are moving from inventory normalization toward active biologics production and process-intensification spending. That should improve revenue visibility relative to capital-equipment-heavy peers, while recurring consumable demand can support incremental gross-margin recovery if utilization remains elevated. The tariff-refund adjustment is non-operating noise; investors should underwrite the trajectory excluding this item rather than annualizing the apparent upside.

Near term, RGEN can rerate if the next earnings print confirms that growth is not concentrated in a small number of customer programs and if management protects its full-year outlook despite tariff and FX uncertainty. Over 6-18 months, wider adoption of real-time analytics raises switching costs and could support a better multiple than filtration-only suppliers, but this requires sustained biopharma funding and commercial-scale biologics volumes. The principal falsifier is a return to customer destocking, visible through weakening order cadence, lower book-to-bill, or guidance that relies on acquisitions or one-time tariff effects rather than organic consumables demand.

Consensus may be underestimating the operating leverage from a recurring-product mix improvement, but the stock is vulnerable if the market has already priced a clean recovery. This is therefore a confirmation trade rather than a conference-commentary chase: validate segment durability, order concentration, and margin conversion at the next quarterly release before sizing aggressively.

Key Decisions for Investors

• Maintain or initiate a modest long RGEN only on a post-conference pullback or after the next earnings release confirms organic growth at or above the company’s full-year midpoint without another guidance-quality caveat; target a 3-6 month holding period and require at least 2:1 upside/downside based on the pre-entry technical stop.
• Use a relative-value expression: long RGEN / short DHR in equal beta-adjusted dollars for 3-6 months if RGEN’s consumables-led growth remains durable. The thesis is that RGEN’s smaller, more specialized exposure to biologics process analytics can outperform diversified life-science peers during a bioprocessing recovery; exit if RGEN’s organic growth falls below DHR’s comparable bioprocessing growth for two consecutive quarters.
• Do not underwrite tariff-related benefit as recurring earnings. Set an alert for the next 10-Q/earnings call covering tariff refund accounting, gross-margin impact, and any revised sourcing costs; a material reversal in tariff treatment or gross-margin guidance is a catalyst to reduce RGEN exposure.
• Watch biopharma capex and funding indicators over the next 1-3 months, particularly large-molecule production commentary from DHR, TMO, and Sartorius. Broad order softness would invalidate the view that RGEN’s strength reflects a sector recovery rather than isolated customer-program timing.